Home » Newsletters » BioWorld Science

BioWorld Science

May 23, 2017

View Archived Issues

ALX-1141 to enter clinical development for the treatment of osteoarthritis

Rasagiline does not add benefit to standard therapy in ALS trial

Proof-of-concept study finds potassium-channel opener ezogabine ameliorates depression

Complete disease correction using gene therapy in novel model of muccopolysaccharidosis type IIID

Phase I results for CPI-613 plus modified FOLFIRINOX in patients with metastatic pancreatic cancer

Cariprazine granted positive opinion in Europe for the treatment of schizophrenia

FDA grants rare pediatric disease designation for EF-022

AC Immune enters research collaboration with Essex Bio-Technology

EMA committee gives positive opinion to brodalumab for plaque psoriasis

eFFECTOR Therapeutics identifies novel MNK1/2 inhibitors

Emmyon patents new furostan-3-ol derivatives

NDUFS7 gene polymorphism tied to obsessive-compulsive disorder risk

University of Dundee and Corbin Therapeutics agree to identify USP15 inhibitors

Shire gives update on phase I/II study of SHP-656 for hemophilia A

Xynomic Pharma and UCSF to conduct phase II/III study of abexinostat in RCC

FDA approves Actemra as first therapy to treat giant cell arteritis

Nektar and Takeda to explore combinations of NKTR-214

Otsuka reports topline results from phase III study of tolvaptan in ADPKD

ViaCyte cleared to begin trial of PEC-Direct in U.S. and Canada

EMA committee recommends approval of Oxervate for neurotrophic keratitis

Celgene reports positive results from RADIANCE study of ozanimod

New mouse model of pulmonary hypertension induced by oxidized lipids presented

FDA approves Kevzara for rheumatoid arthritis

Zealand reports phase IIa results for dasiglucagon in type 1 diabetes